Q&A-SomaxBio

Q:

What is iPSC?

A:

Human induced pluripotent stem cells (iPSCs) are pluripotent stem cells obtained through reprogramming methods that reverse differentiated human somatic cells back to a pluripotent state. When cultured in a feeder‑free, chemically defined iPSC maintenance medium, these cells can proliferate stably and exhibit morphological characteristics, cellular phenotypes, and gene expression patterns similar to those of human embryonic stem cells (hESCs).

Q:

What are the features and advantages of Soma iPSC cell products?

A:

1，Provide ethical approval number with full traceability 2，Provide international stem cell registration number for direct citation in publications 3，Low passage number and supply the latest characterization reports 4，Wide range of cell sources — over 20 cell lines available 5，Validated through multiple cell and organoid differentiation assays 6，One‑on‑one technical guidance to help customers culture cells successfully 7，Over 10 years of focus on iPSCs, offering a one‑stop iPSC solution

Q:

How to choose between heterozygous and homozygous iPSC disease models?

A:

The choice between heterozygous and homozygous iPSC disease models primarily depends on the genetic mode of inheritance. For autosomal dominant disorders, heterozygous models are preferred; for autosomal recessive disorders, homozygous models are the first choice, while heterozygous models can serve as asymptomatic carrier controls. On this basis, the final decision should be determined by the specific research question and control design. If the research involves dosage effects, constructing an allelic series including wild‑type, heterozygous, and homozygous lines is ideal.

Q:

iPSC line generation methods and turnaround time?

A:

iPSC line generation can be performed using various somatic cell sources, such as PBMCs isolated from blood, amniotic fluid cells, skin fibroblasts, etc. Reprogramming factors (Oct4, Sox2, Klf4, c-Myc) are delivered into the cells using Sendai virus or episomal plasmid electroporation. Cells are cultured in a xeno-free induction system, and clones are picked and expanded. After line establishment, the cells undergo 8 characterization services and 2 quality control tests. The success rate of line generation exceeds 99%, and the entire process from line generation to completion of characterization can be as short as 4 months.

Q:

The significance of establishing iPSC lines from the blood of patients with rare diseases

A:

1，Overcoming the bottleneck of sample scarcity: transforming precious, one‑time samples into permanently usable resources. 2，Deeply dissecting the nature of the disease: providing key models to reveal the pathogenesis of rare diseases at the molecular and cellular levels. 3，Accelerating therapy development: offering an efficient and specific platform for drug screening, gene therapy validation, etc., thereby driving the translation from basic research to clinical treatment. 4，Preserving future hope: retaining the original genetic material for potential future personalized gene/cell therapy.

Q:

Cells exhibit vacuolization.

A:

It may be due to cell aging, prolonged failure to passage in time, and oxidative stress damage. The number of passages should be strictly controlled, low‑passage cells should be cryopreserved promptly, and the culture environment should be optimized.